Commonwealth Equity Services
CLDX icon

Commonwealth Equity Services’s Celldex Therapeutics CLDX Stock Holding History

Commonwealth Equity Services’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,327
Closed -$3K – 2748
2018
Q4 		$3K Buy
1,327
+430
+48% +$2.11K ﹤0.01% 2669
2018
Q3 		$6K Buy
897
+106
+13% +$742 ﹤0.01% 2781
2018
Q2 		$6K Sell
791
-539
-41% -$7.21K ﹤0.01% 2756
2018
Q1 		$46K Sell
1,330
-43
-3% -$1.67K ﹤0.01% 2597
2017
Q4 		$58K Buy
1,373
+560
+69% +$24K ﹤0.01% 2558
2017
Q3 		$35K Sell
813
-660
-45% -$24.7K ﹤0.01% 2487
2017
Q2 		$55K Buy
1,473
+671
+84% +$29.7K ﹤0.01% 2411
2017
Q1 		$43K Buy
+802
New +$41.8K ﹤0.01% 2333
2015
Q2 		– Sell
-709
Closed -$296K – 2205
2015
Q1 		$296K Buy
+709
New +$254K ﹤0.01% 1648
2014
Q3 		– Sell
-4,505
Closed -$1.1M – 2101
2014
Q2 		$1.1M Buy
4,505
+2,586
+135% +$584K 0.01% 812
2014
Q1 		$509K Buy
1,919
+1,360
+243% +$521K 0.01% 1151
2013
Q4 		$203K Buy
+559
New +$215K ﹤0.01% 1689

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Commonwealth Equity Services's CLDX Position: Q1 2019 in Review

Commonwealth Equity Services sold out of Celldex Therapeutics (CLDX) in Q1 2019, closing a stake of 1,327 shares — an estimated $3K sold.

Commonwealth Equity Services first reported a position in CLDX in Q4 2013 and held it in 12 quarters. The position peaked at $1.1M in Q2 2014. 53 funds tracked by Wall St. Rank hold CLDX as of Q1 2019.

  • Commonwealth Equity Services reported no remaining Celldex Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Commonwealth Equity Services sold 1,327 Celldex Therapeutics shares in Q1 2019, an estimated $3K.
  • Commonwealth Equity Services first reported a position in Celldex Therapeutics in Q4 2013 and held it in 12 quarters.
  • Commonwealth Equity Services's Celldex Therapeutics position peaked at $1.1M in Q2 2014.
  • 53 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2019.

Based on Commonwealth Equity Services's 13F filing for Q1 2019, filed 13 May 2019.